Back to top
more

GoodRx (GDRX)

(Real Time Quote from BATS)

$6.18 USD

6.18
649,439

+0.24 (4.04%)

Updated Nov 6, 2024 11:48 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 45% (137 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

AMN Healthcare (AMN) to Post Q3 Earnings: What's in the Cards?

by Zacks Equity Research

AMN Healthcare's (AMN) third-quarter results are likely to reflect solid demand across all its segments.

GoodRx Holdings, Inc. (GDRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

GoodRx Holdings, Inc. (GDRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why GoodRx Holdings, Inc. (GDRX) Could Beat Earnings Estimates Again

by Zacks Equity Research

GoodRx Holdings, Inc. (GDRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Medpace Holdings, Inc. (MEDP) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

NextGen Healthcare (NXGN) Q2 Earnings Beat, FY23 View Up

by Zacks Equity Research

NextGen's (NXGN) second-quarter fiscal 2023 results reflect strength in both its revenue sources.

Catalent (CTLT) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Catalent's (CTLT) Q1 earnings are likely to have been driven by robust segmental performances.

Abiomed (ABMD) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven Q2 sales.

Ecolab (ECL) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Ecolab's (ECL) third-quarter results are likely to reflect continued strength in its Global Industrial segment.

Here's Why GoodRx Holdings, Inc. (GDRX) Looks Ripe for Bottom Fishing

by Zacks Equity Research

GoodRx Holdings, Inc. (GDRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

MD or GDRX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

MD vs. GDRX: Which Stock Is the Better Value Option?

ELV vs. GDRX: Which Stock Is the Better Value Option?

by Zacks Equity Research

ELV vs. GDRX: Which Stock Is the Better Value Option?

GoodRx Holdings, Inc. (GDRX) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

GoodRx Holdings, Inc. (GDRX) delivered earnings and revenue surprises of 50% and 4.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Natera (NTRA) delivered earnings and revenue surprises of -2.04% and 2.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Sera Prognostics, Inc. (SERA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Sera Prognostics, Inc. (SERA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: GoodRx Holdings, Inc. (GDRX) Q2 Earnings Expected to Decline

by Zacks Equity Research

GoodRx Holdings, Inc. (GDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

McKesson (MCK) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

McKesson's (MCK) fiscal first-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.

What's in the Offing for QuidelOrtho (QDEL) in Q2 Earnings?

by Zacks Equity Research

QuidelOrtho's (QDEL) second-quarter results are likely to reflect strength across both its COVID and non-COVID businesses.

AMN Healthcare (AMN) to Post Q2 Earnings: What's in the Cards?

by Zacks Equity Research

AMN Healthcare's (AMN) second-quarter results are likely to reflect solid demand across all its segments.

NextGen Healthcare (NXGN) Beats on Q1 Earnings, Cuts FY23 View

by Zacks Equity Research

NextGen Healthcare's (NXGN) first-quarter fiscal 2023 results reflect strength in its Recurring revenues.

Neogen (NEOG) Q4 Earnings Top Estimates, Gross Margin Up

by Zacks Equity Research

Neogen (NEOG) delivers better-than-expected results for the fiscal fourth quarter, with robust segmental performance driving the top line.

ELV vs. GDRX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ELV vs. GDRX: Which Stock Is the Better Value Option?

GoodRx Holdings, Inc. (GDRX) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

GoodRx Holdings, Inc. (GDRX) delivered earnings and revenue surprises of 25% and 1.74%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

AMN vs. GDRX: Which Stock Is the Better Value Option?

by Zacks Equity Research

AMN vs. GDRX: Which Stock Is the Better Value Option?

AMN Healthcare Services (AMN) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

AMN Healthcare (AMN) delivered earnings and revenue surprises of 7.38% and 3.69%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

GoodRx Holdings, Inc. (GDRX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

GoodRx Holdings, Inc. (GDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.